SAN ANTONIO — Nearly 10 years along patients with high-risk BRCA-positive breast cancers who had been treated with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) following […]

SAN ANTONIO — A comprehensive patient-level meta-analysis of three randomized trials demonstrated that compared with surgery deferral, immediate breast surgery significantly reduces both local progression and […]

Patients with BRCA-mutations and a history of early-onset breast cancer benefited from risk-reducing surgeries, according to new data presented at the San Antonio Breast Cancer Symposium (SABCS) […]

Despite being a targeted therapy, antibody-drug conjugates (ADCs) can cause significant off-target toxicity to the eyes of patients being treated for advanced multiple myeloma or cervical […]

More than a third of all patients with cancer die in hospitals, a figure that has increased slightly in recent years, while deaths at home have […]

SAN DIEGO — Treatment with the oral Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib in combination with venetoclax was associated with improved progression-free survival compared with standard-of-care […]

Glucagon-like peptide 1 (GLP-1) receptor agonists led to a significant reduction in the risk for venous thromboembolism (VTE) among individuals with type 2 diabetes compared with […]

SAN DIEGO — Patients with diffuse large B-cell lymphoma (DLBCL) continue to show superior progression-free survival at 5 years with first-line pola-R-CHP compared with the R-CHOP […]